Cargando…
Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy
BACKGROUND: Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized antibody recognizing the RON plexin-semaphorin-integrin (PSI) domain with increased...
Autores principales: | Tong, Xiang-Min, Feng, Liang, Suthe, Sreedhar Reddy, Weng, Tian-Hao, Hu, Chen-Yu, Liu, Yi-Zhi, Wu, Zhi-Gang, Wang, Ming-Hai, Yao, Hang-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743155/ https://www.ncbi.nlm.nih.gov/pubmed/31519211 http://dx.doi.org/10.1186/s40425-019-0732-8 |
Ejemplares similares
-
Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials
por: Yao, Hang-Ping, et al.
Publicado: (2020) -
Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019) -
Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy
por: Yao, Hang-Ping, et al.
Publicado: (2019) -
Structure of the Plexin Ectodomain Bound by Semaphorin-Mimicking Antibodies
por: Suzuki, Kei, et al.
Publicado: (2016) -
Evolution and Diversity of Semaphorins and Plexins in Choanoflagellates
por: Junqueira Alves, Chrystian, et al.
Publicado: (2021)